Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE versus PREGABALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE versus PREGABALIN.
DEPAKOTE vs PREGABALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing release of excitatory neurotransmitters (e.g., glutamate, norepinephrine, substance P).
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
Initial: 75 mg orally twice daily; may increase to 150 mg twice daily within 1 week; maximum: 600 mg/day in divided doses.
None Documented
None Documented
Clinical Note
moderatePregabalin + Fluticasone propionate
"The therapeutic efficacy of Fluticasone propionate can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Haloperidol
"The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Pregabalin."
Clinical Note
moderatePregabalin + Fluconazole
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
Terminal elimination half-life is approximately 6.3 hours. In patients with renal impairment, half-life is prolonged (up to 48 hours in anuria). Requires dose adjustment based on creatinine clearance.
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Primarily renal excretion as unchanged drug (92-99% of dose). Approximately 0.1% is metabolized. No biliary or fecal elimination of significance.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The serum concentration of Fluconazole can be increased when it is combined with Pregabalin."